Completed PHASE2 INTERVENTIONAL 6-arm NCT01269515

Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients (OUSCOX2)

Optional Immunomodulating Therapy and Improved Vaccination Responses by Adjuvant Administration of a Cyclooxygenase Type 2 Inhibitor in Antiretroviral naïve HIV-infected Patients and Patients on ART

Sponsor: Dag Kvale

Conditions HIV

Interventions Etoricoxib

Updated 6 times since 2017 Last updated: May 29, 2017 Started: Oct 31, 2010 Primary completion: Nov 30, 2014 Completion: Nov 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01269515, this PHASE2 trial focuses on HIV and remains completed. Sponsored by Dag Kvale, it has been updated 6 times since 2010, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2017 [monthly]

Completed PHASE2

First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dag Kvale
The Research Council of Norway

Data source: Oslo University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oslo, Norway